{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:01:09Z","timestamp":1790910069074,"version":"4.1.0"},"reference-count":51,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Research Foundation","award":["536819681"],"award-info":[{"award-number":["536819681"]}]},{"name":"German Research Foundation","award":["VAL121\/2023"],"award-info":[{"award-number":["VAL121\/2023"]}]},{"name":"German Research Foundation","award":["70115068"],"award-info":[{"award-number":["70115068"]}]},{"name":"German Research Foundation","award":["70115119"],"award-info":[{"award-number":["70115119"]}]},{"name":"IBB Business Team GmbH program ProValid","award":["536819681"],"award-info":[{"award-number":["536819681"]}]},{"name":"IBB Business Team GmbH program ProValid","award":["VAL121\/2023"],"award-info":[{"award-number":["VAL121\/2023"]}]},{"name":"IBB Business Team GmbH program ProValid","award":["70115068"],"award-info":[{"award-number":["70115068"]}]},{"name":"IBB Business Team GmbH program ProValid","award":["70115119"],"award-info":[{"award-number":["70115119"]}]},{"name":"Deutsche Krebshilfe","award":["536819681"],"award-info":[{"award-number":["536819681"]}]},{"name":"Deutsche Krebshilfe","award":["VAL121\/2023"],"award-info":[{"award-number":["VAL121\/2023"]}]},{"name":"Deutsche Krebshilfe","award":["70115068"],"award-info":[{"award-number":["70115068"]}]},{"name":"Deutsche Krebshilfe","award":["70115119"],"award-info":[{"award-number":["70115119"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer characterized by a dense desmoplastic stroma and a highly immunosuppressive tumor microenvironment (TME). The focal adhesion kinase (FAK), a non-receptor tyrosine kinase, is considered a critical regulator of various cellular processes involved in cancer development. FAK inhibitors (FAKi) have proven to be promising therapeutics for cancer treatment including for pancreatic cancer. As monotherapy, however, FAKi showed only a modest effect in clinical studies. In this study, we investigated the cytotoxicity of six FAKi (Defactinib, CEP-37440, VS-4718, VS-6062, Ifebemtinib and GSK2256098) used in clinical trials on five pancreatic tumor cell lines. We further examined whether their anti-tumor activity can be enhanced by combination with the oncolytic coxsackievirus B3 (CVB3) strain PD-H. IC50 analyses identified Defactinib and CEP-37440 as the most potent inhibitors of tumor cell growth. VS-4718, VS-6062, and Ifebemtinib showed slightly lower activity, while GSK2256098 was largely ineffective. The combination of Defactinib, CEP-37440, VS-4718, and VS-6062 with PD-H resulted in varying effects on cytotoxicity, depending on the cell line and the specific FAKi, ranging from no enhancement to a pronounced increase. Using the Chou\u2013Talalay method, we determined combination indices (CI), revealing synergistic, additive, but also antagonistic interactions between the respective FAKi and PD-H. Considering both oncolytic efficacy and the CI, the greatest enhancement in oncolytic activity was achieved when VS-4718 or CEP-37440 was combined with PD-H. These findings indicate that co-treatment with PD-H can potentiate the therapeutic activity of the selected FAKi and may represent a novel strategy to improve treatment outcomes in PDAC.<\/jats:p>","DOI":"10.3390\/ijms26146877","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T13:00:51Z","timestamp":1752757251000},"page":"6877","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sensitivity of Pancreatic Cancer Cell Lines to Clinically Approved FAK Inhibitors: Enhanced Cytotoxicity Through Combination with Oncolytic Coxsackievirus B3"],"prefix":"10.3390","volume":"26","author":[{"given":"Anja","family":"Geisler","sequence":"first","affiliation":[{"name":"Department of Applied Biochemistry, Institute of Biotechnology, Technische Universit\u00e4t Berlin, 10623 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette","family":"Dieringer","sequence":"additional","affiliation":[{"name":"Department of Applied Biochemistry, Institute of Biotechnology, Technische Universit\u00e4t Berlin, 10623 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Elsner","sequence":"additional","affiliation":[{"name":"Department of Applied Biochemistry, Institute of Biotechnology, Technische Universit\u00e4t Berlin, 10623 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Girod","sequence":"additional","affiliation":[{"name":"Department of Applied Biochemistry, Institute of Biotechnology, Technische Universit\u00e4t Berlin, 10623 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7581-7870","authenticated-orcid":false,"given":"Sophie","family":"Van Linthout","sequence":"additional","affiliation":[{"name":"BIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health (BIH), at Charit\u00e9-Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1469-0052","authenticated-orcid":false,"given":"Jens","family":"Kurreck","sequence":"additional","affiliation":[{"name":"Department of Applied Biochemistry, Institute of Biotechnology, Technische Universit\u00e4t Berlin, 10623 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-4350","authenticated-orcid":false,"given":"Henry","family":"Fechner","sequence":"additional","affiliation":[{"name":"Department of Applied Biochemistry, Institute of Biotechnology, Technische Universit\u00e4t Berlin, 10623 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5334\/aogh.4019","article-title":"Global, Regional, and National Burden of Pancreatic Cancer, 1990\u20132019: Results from the Global Burden of Disease Study 2019","volume":"89","author":"Kan","year":"2023","journal-title":"Ann. Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global Cancer Statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/pin.12114","article-title":"Molecular Pathology of Pancreatic Cancer","volume":"64","author":"Saiki","year":"2014","journal-title":"Pathol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Potievskiy, M.B., Nekrasova, L.A., Korobov, I.V., Bykova, E.A., Moshurov, R.I., Sokolov, P.V., Shatalov, P.A., Falaleeva, N.A., Petrov, L.O., and Trifanov, V.S. (2025). Prognostic Impact of Phenotypic and Genetic Features of Pancreatic Malignancies. Life, 15.","DOI":"10.3390\/life15040635"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"eabg3449","DOI":"10.1126\/scisignal.abg3449","article-title":"Fibrous Stroma: Driver and Passenger in Cancer Development","volume":"15","author":"Sharma","year":"2022","journal-title":"Sci. Signal"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 Disrupts Pancreatic Cancer Stroma and Exerts Antitumor Effects","volume":"9","author":"Laquente","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chakkera, M., Foote, J.B., Farran, B., and Nagaraju, G.P. (2024). Breaking the Stromal Barrier in Pancreatic Cancer: Advances and Challenges. Biochim. Biophys. Acta Rev. Cancer, 1879.","DOI":"10.1016\/j.bbcan.2023.189065"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7956","DOI":"10.3748\/wjg.v27.i46.7956","article-title":"T Cells in Pancreatic Cancer Stroma","volume":"27","author":"Goulart","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Muller, M., Haghnejad, V., Schaefer, M., Gauchotte, G., Caron, B., Peyrin-Biroulet, L., Bronowicki, J.-P., Neuzillet, C., and Lopez, A. (2022). The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges. Cancers, 14.","DOI":"10.3390\/cancers14040995"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel\/Gemcitabine Versus Nab-Paclitaxel\/Gemcitabine in Patients with Untreated, Metastatic Pancreatic Ductal Adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/ncb3340","article-title":"Macrophage-Secreted Granulin Supports Pancreatic Cancer Metastasis by Inducing Liver Fibrosis","volume":"18","author":"Nielsen","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tai, Y.-L., Chen, L.-C., and Shen, T.-L. (2015). Emerging Roles of Focal Adhesion Kinase in Cancer. Biomed. Res. Int., 2015.","DOI":"10.1155\/2015\/690690"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","article-title":"FAK Signaling in Human Cancer as a Target for Therapeutics","volume":"146","author":"Lee","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s12276-020-0447-4","article-title":"Targeting Focal Adhesion Kinase in Cancer Cells and the Tumor Microenvironment","volume":"52","author":"Murphy","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pharmthera.2013.12.003","article-title":"The Role of FAK in Tumor Metabolism and Therapy","volume":"142","author":"Zhang","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in Cancer: Mechanistic Findings and Clinical Applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1042\/BST20220162","article-title":"Focal Adhesion Kinase Priming in Pancreatic Cancer, Altering Biomechanics to Improve Chemotherapy","volume":"50","author":"Murphy","year":"2022","journal-title":"Biochem. Soc. Trans."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chuang, H.-H., Zhen, Y.-Y., Tsai, Y.-C., Chuang, C.-H., Hsiao, M., Huang, M.-S., and Yang, C.-J. (2022). FAK in Cancer: From Mechanisms to Therapeutic Strategies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031726"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-11-0261","article-title":"Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment","volume":"10","author":"Stokes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A Phase I, Pharmacokinetic and Pharmacodynamic Study of GSK2256098, a Focal Adhesion Kinase Inhibitor, in Patients with Advanced Solid Tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","article-title":"A Phase I Study of VS-6063, a Second-Generation Focal Adhesion Kinase Inhibitor, in Patients with Advanced Solid Tumors","volume":"33","author":"Jones","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11523-018-00617-1","article-title":"Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies","volume":"14","author":"Steeghs","year":"2019","journal-title":"Targ. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","article-title":"Phase 2 Study of the Focal Adhesion Kinase Inhibitor Defactinib (VS-6063) in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer","volume":"139","author":"Gerber","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11523-019-00620-0","article-title":"Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors","volume":"14","author":"Doi","year":"2019","journal-title":"Target. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2022.12.001","article-title":"Overcoming Resistance of Stroma-Rich Pancreatic Cancer with Focal Adhesion Kinase Inhibitor Combined with G47\u0394 and Immune Checkpoint Inhibitors","volume":"28","author":"Yamada","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"A091","DOI":"10.1158\/1538-7445.PANCA2023-A091","article-title":"Abstract A091: The RAF\/MEK Clamp Avutometinib as the Backbone of Therapy for Pancreatic Cancer: Novel Combinations with Standard of Care Chemotherapy, FAK Inhibitors, KRAS G12D Inhibitors and\/or Autophagy Inhibitors","volume":"84","author":"Coma","year":"2024","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.20892\/j.issn.2095-3941.2020.0273","article-title":"Inhibition of Focal Adhesion Kinase Enhances Antitumor Response of Radiation Therapy in Pancreatic Cancer through CD8+ T Cells","volume":"18","author":"Osipov","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.omto.2023.03.001","article-title":"Triple Combination Therapy for Pancreatic Cancer Remodels Stroma and Improves Survival","volume":"29","author":"Kaur","year":"2023","journal-title":"Mol. Ther-Oncolytics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an Oncolytic Virus-Based Immunostimulatory Gene Therapy, Combined with Chemotherapy for Unresectable or Metastatic Pancreatic Cancer (LOKON001): Results from Arm 1 of a Non-Randomised, Single-Centre, Phase 1\/2 Study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/j.gastro.2022.06.027","article-title":"Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy","volume":"163","author":"Blair","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","article-title":"Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study","volume":"28","author":"Lim","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic Viruses: A New Class of Immunotherapy Drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/156800907780058817","article-title":"Clinical Trials with Oncolytic Adenovirus in China","volume":"7","author":"Yu","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_36","first-page":"115","article-title":"Gene Medicine for Cancer Treatment: Commercially Available Medicine and Accumulated Clinical Data in China","volume":"2","author":"Ma","year":"2009","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A Phase I\/II Study of Triple-Mutated Oncolytic Herpes Virus G47\u2206 in Patients with Progressive Glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hazini, A., Dieringer, B., Klingel, K., Pryshliak, M., Geisler, A., Kobelt, D., Daberkow, O., Kurreck, J., Linthout, S.V., and Fechner, H. (2021). Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H. Viruses, 13.","DOI":"10.3390\/v13101918"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1089\/hum.2018.036","article-title":"Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma","volume":"29","author":"Hazini","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Geisler, A., Dieringer, B., Elsner, L., Klopfleisch, R., Kurreck, J., and Fechner, H. (2024). Oncolytic Coxsackievirus B3 Strain PD-H Is Effective Against a Broad Spectrum of Pancreatic Cancer Cell Lines and Induces a Growth Delay in Pancreatic KPC Cell Tumors In Vivo. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252011224"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Girod, M., Geisler, A., Hinze, L., Elsner, L., Dieringer, B., Beling, A., Kurreck, J., and Fechner, H. (2024). Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115618"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7731","DOI":"10.1128\/MCB.22.22.7731-7743.2002","article-title":"Alternative Splicing Controls the Mechanisms of FAK Autophosphorylation","volume":"22","author":"Toutant","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_43","first-page":"4779","article-title":"Increased Expression of FAK Isoforms as Potential Cancer Biomarkers in Ovarian Cancer","volume":"17","author":"Moreno","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.virol.2019.05.020","article-title":"Targeting the Proviral Host Kinase, FAK, Limits Influenza a Virus Pathogenesis and NFkB-Regulated pro-Inflammatory Responses","volume":"534","author":"Bergmann","year":"2019","journal-title":"Virology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas with Somatic NF2 Mutations","volume":"41","author":"Brastianos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.4161\/15384101.2014.949550","article-title":"A Small Molecule FAK Kinase Inhibitor, GSK2256098, Inhibits Growth and Survival of Pancreatic Ductal Adenocarcinoma Cells","volume":"13","author":"Zhang","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1021\/acs.jmedchem.6b00487","article-title":"Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)","volume":"59","author":"Ott","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3892\/or.2021.7979","article-title":"Anaplastic Lymphoma Kinase Inhibitor NVP-TAE684 Suppresses the Proliferation of Human Pancreatic Adenocarcinoma Cells","volume":"45","author":"Duong","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jcmgh.2019.07.004","article-title":"PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating \u03b2-CateninY654","volume":"8","author":"Gao","year":"2019","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6877\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:11:29Z","timestamp":1760033489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":51,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146877"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146877","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}